SymBiosis
VC Fund
Bentonville, United States
SymBiosis is a venture capital firm.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 19%
Last updated:
For AI agents: llms.txt
Industries SymBiosis invests in
Stages SymBiosis invests in
Countries SymBiosis invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jahanara Ali
|
|||
Investment Focus
Industry
- Biotechnology 17 (81%)
- Health Care 15 (71%)
- Medical 9 (43%)
- Biopharma 7 (33%)
- Life Science 6 (29%)
Stage
- Series B 6 (29%)
- Series C 5 (24%)
- Series D 3 (14%)
- Series E 3 (14%)
- Series A 2 (10%)
Country
- United States 13 (62%)
- China 1 (5%)
- Canada 1 (5%)
- France 1 (5%)
- Israel 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jahanara Ali
VP of Business Development
|
VP of Business Development | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
AdvanCell
|
AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $315M / Series D / Jul 15, 2026 | |
Fore Biotherapeutics
|
We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $67.4M / Series D / Jul 07, 2026 | |
SonoThera
|
SonoThera is a biotechnology company that creates non-viral genetic therapies using ultrasound. Its mission is to develop genetic medicines that treat the root cause of human disease. SonoThera is expanding the possibilities of disease treatment with ultrasound-guided nonviral gene therapy for diseases with suboptimal or non-existent treatments. Itaims to improve the lives and health of millions of people. | $125M / Series B / Jun 10, 2026 | |
R1 Therapeutics
|
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug therapies for patients with kidney disease. The company’s primary work centers on advancing AP306, a therapeutic candidate designed to treat hyperphosphatemia—a condition of elevated phosphate levels that commonly affects individuals withchronic kidney disease on dialysis—by blocking key active phosphate transport pathways in the gut. In its operations, R1 Therapeutics works on progressing AP306 through mid- and late-stage clinical studies and aims to bring an alternative treatment option to patients struggling with phosphate management complications associated with chronic kidney disease. | $77.5M / Series A / Mar 17, 2026 | |
CORXEL Pharmaceuticals
|
Jixing Pharmaceuticals develops innovative science and medicines to underserved Chinese patients with serious and life-threatening diseases. | $287M / Series D / Jan 22, 2026 | |
Aeovian Pharmaceuticals
|
Aeovian Pharmaceuticals is a San Francisco Bay Area-based biopharmaceutical company aiming to discover, develop, and commercialize innovative therapeutics for the treatment of rare and age-related diseases. The company is developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression,such as oxidative, cellular and environmental stress.Aeovian Pharmaceuticals was founded in 2012. | $55M / Series B / Dec 16, 2025 | |
|
Sanegene Bio
|
Sanegene Bio is currently operating in stealth mode. | $110M / Series B / Dec 08, 2025 | |
Solve Therapeutics
|
Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics. The company was founded in 2021 and is headquartered in Belmont, California. | $120M / Series A / Nov 17, 2025 | |
ENTEROME
|
Enterome is an integrated company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics.Enterome is focused on the identification of the bioactive molecules that are differentially expressed, secreted and regulated by the gut microbiome, whichplay a central role in the regulation of key aspects of human physiology and the immune system. | $19M / Venture - Series Unknown / Jun 12, 2025 | |
Paradox Immunotherapeutics
|
Paradox Immunotherapeutics is a pharmaceutical company that develops treatments for patients suffering from rare amyloid diseases. It uses an immunotherapy drug design platform to design drugs that harness the body’s own immune system to clear lethal deposits from affected organs and reverse organ damage. | $10M / Venture - Series Unknown / Feb 25, 2025 | |
| See all 21 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does SymBiosis invest in?
SymBiosis invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 21 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact SymBiosis?
Public channels for SymBiosis include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at SymBiosis?
The team at SymBiosis includes Jahanara Ali (VP of Business Development). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
